Prime Medicine, Inc. (NYSEARCA:PRME – Get Rating)'s stock price was up 2.1% during mid-day trading on Thursday . The company traded as high as $18.61 and last traded at $18.61. Approximately 15 shares traded hands during trading, a decline of 100% from the average daily volume of 540,992 shares. The stock had previously closed at $18.22.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on PRME shares. Jefferies Financial Group began coverage on Prime Medicine in a research note on Monday. They set a "buy" rating and a $25.00 price objective on the stock. The Goldman Sachs Group began coverage on shares of Prime Medicine in a report on Monday. They set a "neutral" rating and a $22.00 target price for the company. JPMorgan Chase & Co. began coverage on shares of Prime Medicine in a report on Monday. They set an "overweight" rating and a $27.00 target price for the company. Finally, Morgan Stanley began coverage on shares of Prime Medicine in a report on Monday. They set an "equal weight" rating and a $23.00 target price for the company.
Get Prime Medicine alerts:Prime Medicine Trading Up 3.8 %
The company's fifty day moving average price is $19.55 and its 200-day moving average price is $19.99.
Insider Transactions at Prime Medicine
In other Prime Medicine news, Director Thomas Cahill purchased 400,000 shares of the company's stock in a transaction dated Monday, October 24th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $6,800,000.00. Following the purchase, the director now directly owns 5,305,679 shares of the company's stock, valued at approximately $90,196,543. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, major shareholder 2019 Gp L.L.C. Gv bought 800,000 shares of the stock in a transaction that occurred on Monday, October 24th. The shares were bought at an average price of $17.00 per share, for a total transaction of $13,600,000.00. Following the purchase, the insider now owns 11,522,248 shares in the company, valued at $195,878,216. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Thomas Cahill bought 400,000 shares of the stock in a transaction that occurred on Monday, October 24th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $6,800,000.00. Following the purchase, the director now owns 5,305,679 shares in the company, valued at approximately $90,196,543. The disclosure for this purchase can be found here.Prime Medicine Company Profile
(Get Rating)
Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
Further Reading
- Get a free copy of the StockNews.com research report on Prime Medicine (PRME)
- BJ's Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
- NVIDIA's Rally Picks Up Pace Into Year End
- Nothing Micro About Super Micro Computer's Price & Earnings Gains
- Why Are Bears Still Going Short on AGNC Investment?
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.